United Kingdom Life sciences have been steadily losing ground in the UK with a significant drop in global R&D investments and a decreasing number of patients enrolled in clinical trials. The British government has announced a GBP 650 million “Life Sci for Growth” package along with some pro-innovation regulation and a review…
UK The UK government has decided to go ahead with a much-debated increase in the revenue clawback rate —from 24.4 percent to 27.5 percent— for drugmakers subject to its Statutory Scheme for branded medicines. The Association of the British Pharmaceutical Industry (ABPI) warns that this latest move to reduce spending will…
UK Pricing and market access have become increasingly hot topics in recent years, as healthcare systems across the world attempt to balance their own financial sustainability with securing the latest medical innovations and the premium costs associated with them. Health inequity and access disparities exist between both rich and developing countries,…
United Kingdom US biotech Moderna – producer of a messenger RNA (mRNA) COVID-19 vaccine that has found its way into 75 million arms in the US alone and generated USD 12 billion in profit for the firm last year – has announced a new GBP one billion investment into a UK manufacturing…
United Kingdom Just one year after the UK government published its Life Science Vision, outlining the ambitions of the government and the life science sector for the next 10 years, the Association of the British Pharmaceutical Industry (ABPI) has appointed a new president who will take on the plan. The Association of…
Brexit The European Medicines Agency has cut Britain out of its contracts 7 months ahead of Brexit. “You might have been working on a cancer drug for decades and built up so much expertise that you are the absolute specialist in your field and now have to transfer all your knowledge…
UK Britain, home of the discovery of the world’s first ever vaccine, has long been championing a pharma sub-segment forecast to reach a global market value of USD 49.27 billion by 2022. However, despite possessing the innovators, the infrastructure and the coverage, the UK’s thriving vaccine industry risks being blown off…
UK Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry (ABPI) reveals his staunch faith in the British health service but calls for the NHS to welcome and drive change by enhancing productivity. With positive evolutions in the UK government’s approach to collaborative partnerships, he warns that clarity…
Association of the British Pharmaceutical Industry (ABPI) Taking a look at a key achievement of the ABPI in recent years, we recognize the role you played in negotiating the revised PPRS that was put in place last year. How did the latest revision contribute to taking the research-based industry forward and what has been the impact of…
Association of the British Pharmaceutical Industry (ABPI) What are the priorities on your agenda as the new head of ABPI considering the successes and difficulties the association has experienced in the past? If you look at the recent history of the pharmaceutical industry in the UK, perhaps one of the areas that we have been most successful…
See our Cookie Privacy Policy Here